LabCorp launches test to predict hep C treatment response
This article was originally published in Clinica
Executive Summary
Laboratory Corporation of America (LabCorp) has launched a test to predict patients' responses to certain hepatitis C therapies in the US. The diagnostic, which detects a variant in the IL-28B gene, could be used to identify patients who will do better on combined pegylated interferon alfa/ribavirin therapy. This is important because this drug regimen can be gruelling, but is not effective in all patients. Those who respond best have a particular variant, called CC, of genotype 1 hepatitis C. This discovery was first reported in the 17 September 2009 issue of Nature. Genotype 1 is the most common form of the virus, accounting for around 70% of cases in the US.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.